Fig 1: Inflammatory signaling in PBMCs and cytokine levels of the control subject and DES patient. (a) TLR4, (b) MyD88, (c) p‐IKKαβ, (d) IkBα, (e) p‐P38/P38, (f) p‐ERK/ERK, (g) p‐JNK/JNK. Protein levels obtained by Western blot; (h) IL‐6 and (i) IL‐1Ra, plasma concentration obtained by ELISA. The colored area represents the random error.
Fig 2: The low-dose AAV-IL1Ra vector exhibits good pharmacodynamic effects in a surgically induced OA rat model. Note: (A), body weight (g); (B), joint diameter (mm); (C), joint swelling (%); (D), X-ray score; (E), representative X-ray images of various dose groups in the OA rat model. Low dose: 5 × 1010 vg/joint; high dose: 1 × 1011 vg/joint; n = 10. Compared with PBS, *** p < 0.001, **** p < 0.0001 (vehicle group); compared with the vehicle group, # p < 0.05, ## p < 0.01, ### p < 0.001 (low-dose AAV9 group); compared with the vehicle group, $ p < 0.05, $$ p < 0.01 (high-dose AAV9 group); compared with the vehicle group, % p < 0.05, %% p < 0.01 (low-dose AAV5 group); compared with the vehicle group, & p < 0.05 (high-dose AAV5 group).
Fig 3: AAV-IL-1Ra gene therapy substantially protects trabecular bone-related indicators in animal models. Note: We evaluated the therapeutic effects of each group on the rat OA model using micro-CT analysis. (A), Bone Volume (BV); (B), Bone Volume/Tissue Volume (BV/TV); (C), Bone Surface/Volume Ratio (BS/BV); (D), Trabecular Thickness (Tb.Th); (E), Trabecular Number (Tb.N); (F), Trabecular Separation (Tb.Sp); (G), Representative Micro-CT images of various dose groups in the OA rat model. Low dose: 5 × 1010 vg/joint; high dose: 1 × 1011 vg/joint; n = 7; compared with PBS, ** p < 0.01, *** p < 0.001 (vehicle group); compared with the vehicle group, # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.0001; compared with high-dose AAV5, $ p < 0.05.
Fig 4: The construction of plasmid cassettes with intron insertion in the transgene CDS region. Note: (A), a schematic illustration detailing the construction of multiple plasmid cassettes, each featuring an intron insertion specifically within the coding sequence (CDS) of the IL-1Ra gene. (B), the quantification of the protein expression levels of IL-1Ra plasmids, achieved via ELISA analysis subsequent to transduction into HEK293 cells (n = 3). (C), a conceptual diagram outlining the design and construction of plasmid cassettes, which incorporate the VH4 intron within the CDS of reporter genes, specifically eGFP and mCherry. (D), the visualization and verification of fluorescent signals emitted by eGFP-intron and mCherry-intron plasmids, utilizing an inverted fluorescence microscope, after these constructs have been transduced into and expressed by HEK293 cells. Compared with No. 0, ns means not significant (p > 0.05), * p < 0.05, ** p < 0.01, **** p < 0.0001; scale bar: 50 μL.
Supplier Page from Abcam for Human IL-1RA ELISA Kit